[
    [
        {
            "time": "",
            "original_text": "贝达药业：巴替利单抗注射液治疗宫颈癌获批临床试验",
            "features": {
                "keywords": [
                    "贝达药业",
                    "巴替利单抗",
                    "宫颈癌",
                    "临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：巴替利单抗注射液治疗宫颈癌获批临床试验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业 PD-1 巴替利单抗获批临床",
            "features": {
                "keywords": [
                    "贝达药业",
                    "PD-1",
                    "巴替利单抗",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业 PD-1 巴替利单抗获批临床",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：埃克替尼一线治疗EGFR突变的晚期NSCLC患者的适应症在2014年已经获批",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "EGFR突变",
                    "NSCLC",
                    "适应症",
                    "2014年"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：埃克替尼一线治疗EGFR突变的晚期NSCLC患者的适应症在2014年已经获批",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：目前，免疫学高级总监徐汶新博士负责大分子项目的开发工作",
            "features": {
                "keywords": [
                    "贝达药业",
                    "免疫学",
                    "徐汶新",
                    "大分子项目",
                    "开发工作"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：目前，免疫学高级总监徐汶新博士负责大分子项目的开发工作",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        }
    ]
]